McKinsey January 29, 2025
Even though the biopharma supply chain is a dynamic and complex part of the pharmaceutical industry, private equity investors can find growth and value creation opportunities. Here’s how.
The biopharma industry is going through disruptive times. Although private equity (PE) funding and deal activity in biotech surged in the years leading up to the COVID-19 pandemic, and peaked in 2021 amid the unprecedented speed and innovation of the vaccine development process, both started receding once the pandemic ended.
The impact of this volatility has been felt throughout the pharma value chain, including by service providers that play an integral part in the development of innovative products. According to our research, PE deal activity in pharma services dropped 15 percent per...
Today's Sponsors
Today's Sponsor